Press Releases
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
PRESS RELEASE For immediate release Quebec, Canada – February 19, 2026 — Devonian Health Group Inc. (“Devonian” or the Company) (TSXV: GSD; OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human...
Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
PRESS RELEASE For immediate release Quebec, Canada – February 17, 2026 — Devonian Health Group Inc. (“Devonian” or the Company) (TSXV: GSD; OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally filed in two recent patent...
DEVONIAN REPORTS ADDITIONAL MOLECULAR DATA FROM MASH LIVER STUDY
PRESS RELEASE For immediate release Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver. QUÉBEC, Quebec, February 12, 2026 – Devonian Health Group Inc....
DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
PRESS RELEASE For immediate release Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs Compelling results compared to Pirfenidone, a drug used to treat idiopathic pulmonary...
Devonian appoints Dennis Turpin as chief financial officer and provides updates on stock options grant
QUÉBEC, Québec, February 2, 2026 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, is pleased to announce that it has appointed...
Devonian announces share consolidation in further preparation for potential U.S. listing
QUÉBEC, Québec, January 20, 2026 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF) is pleased to announce that, in connection with an evaluation of an additional listing of the Company’s common shares (“Common Shares”) on a U.S....
Devonian Health Group Announces Grant of Stock Options
PRESS RELEASE For immediate distribution Québec, QUEBEC, December 19, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical Company specializing in the development of prescription drugs targeting...
Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update
PRESS RELEASE For immediate distribution Company continues preclinical studies for Thykamine™ in MASH and Fibrosis, furthering the understanding of Thykamine™’s mechanism of action. Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs published in the peer...
Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent
PRESS RELEASE For immediate release QUÉBEC, Dec. 4, 2025 - Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting fibroinflammatory...
Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
Fourth quarter distribution revenues of $1.3 million Fourth quarter net loss of $0.4 million, $0.003 per share Annual distribution revenues of $23.6 million Annual net loss of $6 million, $0.041 per share Devonian is debt free with $7 million in cash as of July 31,...